TrialMovement disorders : official journal of the Movement Disorder Society2021

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.

Aleksandar Videnovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.